The International Society for Neglected Tropical Diseases (ISNTD), meeting May 20-21, 2015 at the Wellcome Trust in London, asked Replikins Ltd to form a Vaccine Consortium to apply the new Replikins technology of Surveillance and Synthetic Vaccine
production, testing and distribution to the largely unmet needs of the billions of people with Neglected Tropical Diseases (linked here and below in Reference 5).
The idea of the synthetic vaccine
is that it contains no genome it's virus free," he tolds.
UK scientists have developed a synthetic vaccine
for foot-andmouth disease (FMD) virus.
Now, scientists from the UK have developed a new method to create an entirely synthetic vaccine
that doesn't rely on using live infectious virus, which means it is much safer, the BBC reported.
A SYNTHETIC vaccine
based on nanotechnology holds out the promise of halting autoimmune diseases such as Crohn's and rheumatoid arthritis, it was reported yesterday.
Cuban researchers have developed the first synthetic vaccine
against a bacteria that causes pneumonia and meningitis, a breakthrough aimed at lowering the cost of immunizing children in poorer countries, reports Reuters (Nov.
The blood concentrations of antibodies induced by the synthetic vaccine
were as high or higher than levels in blood from people of Burkina Faso, Mali, and Colombia--all endemic malarial zones--who had donated blood samples.
Biomira, through patent licensing agreements with the Dana-Farber Cancer Institute (Boston, MA) and the Imperial Cancer Research Fund (London, England), has secured exclusive world-wide rights to any MUC-1 synthetic vaccine
Ross is taking a novel approach by examining the use of a synthetic vaccine
created from genetic sequences of many different flu viruses.
Washington, June 9 ( ANI ): Researchers have developed and tested a synthetic vaccine
in mice and found it to be effective in killing human papillomavirus-derived cancer, a virus linked to cervical cancers among others.
The products resulting from this collaboration will leverage Selecta's proprietary Synthetic Vaccine
Particle (SVP[TM]) platform which has unique capabilities to engineer nanoparticles with the ideal structure and composition to produce immune tolerance by balancing the overactive response to specific allergy-causing antigens.
Selecta is applying its proprietary Synthetic Vaccine
Particle (SVP[TM]) platform to advance a robust pipeline of vaccine candidates for the prevention and treatment of a number of serious diseases, including infectious diseases, smoking cessation, autoimmune diseases and allergies.